EphA2/ephrinA1与人脑胶质瘤发生的关系及靶向治疗潜能探讨

郑俊青; 安聪娟; 方艳伟

doi:10.3969/j.issn.1000-8179.2013.08.014

EphA2/ephrinA1与人脑胶质瘤发生的关系及靶向治疗潜能探讨

doi: 10.3969/j.issn.1000-8179.2013.08.014

河北医科大学第二医院神经外二科（石家庄市050000）

详细信息

通讯作者:
方艳伟 1149311296@qq.com

计量
- 文章访问数: 10
- HTML全文浏览量: 26
- PDF下载量: 1
- 被引次数: 0
出版历程
- 收稿日期: 2012-06-25
- 修回日期: 2012-09-24

EphA2 receptor and ephrinA1 ligand in gliomas

Department of Neurosurgery, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China

More Information

Corresponding author: Yanwei FANG; E-mail: 1149311296@qq.com

摘要

摘要: 恶性脑胶质瘤发生发展同酪氨酸蛋白激酶(receptor tyrosine kinases, RTK)受体EphA2及其配体ephrinA1的表达功能与肿瘤细胞中的信号转导密切相关, EphA2和ephrinA1的表达受肿瘤细胞种类和微环境的影响, 进而诱导肿瘤细胞及相关细胞信号转导, 产生相应的生物学行为。EphA2、ephrinA1系统有望成为恶性脑胶质瘤药物治疗的新靶点。
- 神经胶质瘤 /
- 蛋白酪氨酸激酶类 /
- 受体EphA2 /
- 配体ephrinA1
Abstract: The functions and roles of EphA2 receptor and ephrinA1 ligand in different cell types are correlated with the development and maintenance of gliomas.Moreover, their functions in tumorigenesis and tumor progression are complex and dependent on the type and microenvironment of tumor cells.These variables affect the expression of EphA2 and ephrinA1 proteins, the pathways through which they induce cell signaling transduction, and the corresponding consequences of that signaling on biological behaviors.The function of the EphA2 and ephrinA1 system is expected to be the new target of medicinal treatment for cerebral gliomas.
- gliomas /
- protein-tyrosine kinases /
- EphA2 receptor /
- ephrinA1 ligand

HTML全文

参考文献(19)

[1]	Li X, Wang L, Gu JW, et al. Up-regulation of EphA2 and down-regulation of EphrinA1 are associated with the aggressive phenotype and poor prognosis of malignant glioma[J]. Tumour Bi ol, 2010, 31(5): 477-488. doi: 10.1007/s13277-010-0060-6
[2]	Wang LF, Fokas E, Bieker M, et al. Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblas toma multiforme patients[J]. Oncol Rep, 2008, 19(1): 151-156.
[3]	Okada H, Low KL, Kohanbash G, et al. Expression of glioma-as sociated antigens in pediatric brain stem and non-brain stem glio mas[J]. J Neurooncol, 2008, 88(3): 245-250. doi: 10.1007/s11060-008-9566-9
[4]	Wykosky J, Gibo DM, Stanton C, et al. Interleukin-13 receptor al pha 2, EphA2, and Fos-related antigen 1 as molecular denomina tors of high-grade astrocytomas and specific targets for combinato rial therapy[J]. Clin Cancer Res, 2008, 14(1): 199-208. doi: 10.1158/1078-0432.CCR-07-1990
[5]	Li X, Wang Y, Wang Y, et al. Expression of EphA2 in human as trocytic tumors: correlation with pathologic grade, proliferation and apoptosis[J]. Tumour Biol, 2007, 28(3): 165-172. doi: 10.1159/000103010
[6]	Liu DP, Wang Y, Koeffler HP, et al. Ephrin-A1 is a negative regu lator in glioma through down-regulation of EphA2 and FAK[J]. Int J Oncol, 2007, 30(4): 865-871.
[7]	Wykosky J, Palma E, Gibo DM, et al. Soluble monomeric Ephri nA1 is released from tumor cells and is a functional ligand for the EphA2 receptor[J]. Oncogene, 2008, 27(58): 7260-7273. doi: 10.1038/onc.2008.328
[8]	Miao H, Li DQ, Mukherjee A, et al. EphA2 mediates ligand-depen dent inhibition and ligand-independent promotion of cell migra tion and invasion via a reciprocal regulatory loop with Akt[J]. Can cer Cell, 2009, 16(1): 9-20. doi: 10.1016/j.ccr.2009.04.009
[9]	Gopal U, Bohonowych JE, Lema-Tome C, et al. A novel extracel lular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion[J]. PLoS One, 2011, 6(3): e17649. doi: 10.1371/journal.pone.0017649
[10]	Liu F, Park PJ, Lai W, et al. A genome-wide screen reveals func tional gene clusters in the cancer genome and identifies EphA2 as amitogen in glioblastoma[J]. Cancer Res, 2006, 66(22): 10815-10823. doi: 10.1158/0008-5472.CAN-06-1408
[11]	Folkman J. Angiogenesis in cancer, vascular, rheumat oid and other diseases[J]. Nature Med, 1995, 1(1): 27-31. doi: 10.1038/nm0195-27
[12]	Zhou N, Zhao WD, Liu DX, et al. Inactivation of EphA2 promotes tight junction formation and impairs angiogenesis in brain endotheli al cells[J]. Microvasc Res, 2011, 82(2): 113-121. doi: 10.1016/j.mvr.2011.06.005
[13]	Giorgio C, Hassan Mohamed I, Flammini L, et al. Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation[J]. PLoS One, 2011, 6(3): e18128. doi: 10.1371/journal.pone.0018128
[14]	Li JJ, Liu DP, Liu GT, et al. EphrinA5 acts as a tumor suppressor in glioma by negative regulation of epidermal growth factor receptor[J]. Oncogene, 2009, 28(15): 1759-1768. doi: 10.1038/onc.2009.15
[15]	Ueda R, Low KL, Zhu X, et al. Spontaneous immune responses against glioma-associated antigens in a long term survivor with ma lignant glioma[J]. J Transl Med, 2007, 5: 68. doi: 10.1186/1479-5876-5-68
[16]	Ueda R, Fujita M, Zhu X, et al. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeu tic efficacy of glioma-associated antigen peptide vaccines[J]. Clin Cancer Res, 2009, 15(21): 6551-6559.
[17]	Okada H, Kalinski P, Ueda R, et al. Induction of CD8+T-cell re sponses against novel glioma-associated antigen peptides and clinical activity by vaccinations with{alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and car boxymethylcellulose in patients with recurrent malignant glioma[J]. JClin Oncol, 2011, 29(3): 330-336. doi: 10.1200/JCO.2010.30.7744
[18]	Wu N, Zhao X, Liu M, et al. Role of microRNA-26b in glioma de velopment and its mediated regulation on EphA2[J]. PLoS One, 2011, 6(1): e16264. doi: 10.1371/journal.pone.0016264
[19]	Zhou Z, Yuan X, Li Z, et al. RNA interference targeting EphA2 inhibits proliferation, induces apoptosis, and cooperates with cytotoxic drugs in human glioma cells[J]. Surg Neurol, 2008, 70(6): 562-568. doi: 10.1016/j.surneu.2008.04.031